-
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| ISIN | CA98420Q2071 |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| Market Cap | 3M |
|---|---|
| PE Ratio | None |
| Target Price | 14.0358 |
| Beta | 0.1 |
| Dividend Yield | None |
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for XRTX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026